Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) Initiative
Ofir Wolach(Tel Aviv University), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Srilakshmi Bathini(University of Alabama at Birmingham), Tsila Zuckerman(Johannes Gutenberg University Mainz), Boaz Nachmias, Wesleigh Edwards(Scripps MD Anderson Cancer Center), Sameem Abedin(Medical College of Wisconsin), Daniel A. Pollyea(University of Colorado Denver), Pankit Vachhani(University of Alabama at Birmingham), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Melissa Montez, Evan C. Chen(Dana-Farber Cancer Institute), Kendra Sweet(Moffitt Cancer Center), Catherine Lai(University of Pennsylvania), Pinkal Desai(NewYork–Presbyterian Hospital), Yakir Moshe(Tel Aviv University), Catherine L. Miller(AbbVie (United States)), Moshe Grunspan(Weizmann Institute of Science), Sangmin Lee(Janssen (United States)), Annie Guérin(Group for Research in Decision Analysis), Wei‐Han Cheng, Esprit Ma, Cat N. Bui(AbbVie (United States)), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Marin Xavier(Scripps Health), Jessica Maitland(Group for Research in Decision Analysis)
Cited by 2
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621